# TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

> **NCT06532799** · PHASE1,PHASE2 · RECRUITING · sponsor: **Essen Biotech** · enrollment: 75 (estimated)

## Conditions studied

- Stomach Cancer
- Stomach Cancer Recurrent
- Stomach Cancer, Adenocarcinoma
- Esophageal Cancer
- Esophageal Cancer Metastatic to Bone
- Esophageal Cancer Metastatic to Lung
- Esophageal Cancer Metastatic to Liver

## Interventions

- **BIOLOGICAL:** Tumor Infiltrating Lymphocytes (TIL)
- **DRUG:** Cyclophosphamid
- **DRUG:** Fludarabine
- **DRUG:** Interleukin-2
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06532799
- **Lead sponsor:** Essen Biotech
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-12-28
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532799, "TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06532799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*